Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656890 · ClinicalTrials.gov registry record · Phase 2
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00656890 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 110 participants.
The verdict
NCT00656890, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of the MDX-1100 regimen in subjects with active Ulcerative colitis(UC) and determine the response rate at day 57 in patients administered MDX-1100.
Interventions
- BIOLOGICAL sterile saline for injection
- BIOLOGICAL MDX-1100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656890
The ClinicalTrials.gov registry entry for NCT00656890 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sterile saline for injection is the first listed.
NCT00656890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656890 about?
NCT00656890 is a clinical study titled "A Study of MDX-1100 in Subjects With Active Ulcerative Colitis". The purpose of this study is to determine the safety and tolerability of the MDX-1100 regimen in subjects with active Ulcerative colitis(UC) and determine the response rate at day 57 in patients administered MDX-1100.
What is the current status of trial NCT00656890?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2008-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00656890?
The interventions under investigation include: sterile saline for injection (BIOLOGICAL), MDX-1100 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00656890?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.